Medexus Pharmaceuticals (TSE:MDP) Trading Up 4.1% - What's Next?

Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) was up 4.1% during trading on Tuesday . The company traded as high as C$2.81 and last traded at C$2.81. Approximately 7,802 shares traded hands during trading, a decline of 93% from the average daily volume of 106,779 shares. The stock had previously closed at C$2.70.

Analyst Ratings Changes

Several brokerages have recently weighed in on MDP. Stifel Canada cut shares of Medexus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Raymond James upgraded Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 price target on the stock in a report on Wednesday, January 8th. Ventum Financial upped their price objective on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a "buy" rating in a research note on Thursday, January 30th. Stifel Nicolaus lowered Medexus Pharmaceuticals from a "buy" rating to a "hold" rating and cut their target price for the company from C$6.00 to C$3.45 in a research note on Friday, February 7th. Finally, Leede Financial raised shares of Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research report on Wednesday, January 22nd. Two analysts have rated the stock with a hold rating, one has issued a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of C$5.49.

Medexus Pharmaceuticals Trading Down 1.4 %

The stock has a market capitalization of C$61.79 million, a PE ratio of 13.20 and a beta of 1.96. The company's 50-day moving average is C$2.52 and its 200 day moving average is C$2.88.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.